Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Saved in:
Bibliographic Details
Title: Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.
Authors: Oswald LB; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. Laura.Oswald@Moffitt.org., Li X; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Gudenkauf LM; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA., De Avila G; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Scheiber-Camoretti D; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Small BJ; School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Gonzalez BD; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Hoogland AI; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Nguyen O; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Rodriguez Y; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Crowder SL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Parker NH; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Carson TL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Vinci CE; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Baz RC; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA., Shain KH; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA., Blue B; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA., Grajales-Cruz A; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA., Matte K; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Kale B; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Kaldas D; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Perna F; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Alsina M; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Freeman CL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Castaneda Puglianini O; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Nishihori T; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Liu H; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Jim HSL; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA., Peres LC; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA., Hansen DK; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
Source: Bone marrow transplantation [Bone Marrow Transplant] 2026 Jul; Vol. 61 (7), pp. 864-872. Date of Electronic Publication: 2026 May 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5365
DOI:10.1038/s41409-026-02899-w